|
|||||
|
|
An Economic Comparison of Risperidone and Olanzapine Use within an Integrated Managed Mental Health Program |
|
| Authors: | Michael Johnsrud M Lynn Crismon Ann Thompson Amy Grogg |
| Institution: | (1) Center for Pharmacoeconomic Studies, The University of Texas at Austin, Austin, TX, USA;(2) Regional Outcomes Research, Janssen Pharmaceutica, Titusville, NJ, USA;(3) Outcomes Research and Biostatistics, Janssen Pharmaceutica, Titusville, NJ, USA;(4) Center for Pharmacoeconomic Studies, The University of Texas at Austin, 1, University Station, MC #A 1910, Austin, 78712, TX, USA |
| Abstract: | This study assessed differences in total mental health care costs for 1 year following initiation of risperidone or olanzapine in individuals within NorthSTAR, an integrated managed mental health pilot project. A retrospective database analysis of individuals with schizophrenia or schizoaffective disorder and newly started on either agent was conducted. Antipsychotic medication costs were significantly lower for individuals prescribed risperidone than olanzapine ($1763 versus $2582; p<0.001). Individuals prescribed risperidone had lower (but not significant) expenditures for mental health services ($4714 versus $5077; p=0.792), as well as total mental health care costs ($7407 versus $9011; p=0.255). |
| Keywords: | mental health costs olanzapine risperidone schizophrenia |
| 本文献已被 PubMed SpringerLink 等数据库收录！ | |